Adaptimmune Therapeutics plc

3.57-0.0400-1.11%Vol 348.77K1Y Perf -60.33%
Jul 30th, 2021 16:00 DELAYED
BID3.56 ASK3.57
Open3.57 Previous Close3.61
Pre-Market- After-Market3.55
 - -  -0.02 -0.56%
Target Price
9.00 
Analyst Rating
Moderate Buy 2.00
Potential %
152.10 
Finscreener Ranking
★★★+     51.50
Insiders Trans % 3/6/12 mo.
-/-/-65 
Value Ranking
★★★+     54.09
Insiders Value % 3/6/12 mo.
-10/-10/-23 
Growth Ranking
★★+     49.59
Insiders Shares Cnt. % 3/6/12 mo.
64/64/69 
Income Ranking
 —    -
Market Cap555.03M 
Earnings Rating
Buy
Price Range Ratio 52W %
2.65 
Earnings Date
9th Aug 2021

Today's Price Range

3.513.64

52W Range

3.3710.93

5 Year PE Ratio Range

-4.20-6.20

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-1.38%
1 Month
-16.20%
3 Months
-36.93%
6 Months
-34.62%
1 Year
-60.33%
3 Years
-63.50%
5 Years
-56.03%
10 Years
-

TickerPriceChg.Chg.%
ADAP3.57-0.0400-1.11
AAPL145.860.22000.15
GOOG2 704.42-26.3900-0.97
MSFT284.91-1.5900-0.55
XOM57.57-1.3600-2.31
WFC45.94-0.5600-1.20
JNJ172.200.02000.01
FB356.30-2.0200-0.56
GE12.95-0.3400-2.56
JPM151.78-1.2200-0.80
Financial StrengthValueIndustryS&P 500US Markets
11.20
11.50
0.06
0.07
-
Leverage Ratio 1.30
ProfitabilityValueIndustryS&P 500US Markets
-
-3 897.80
-3 696.30
-3 265.60
-
RevenueValueIndustryS&P 500US Markets
3.13M
0.02
-58.06
-21.94
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.25-0.244.00
Q04 2020-0.23-0.24-4.35
Q03 2020-0.23-0.230.00
Q02 2020-0.24-0.240.00
Q01 2020-0.13-0.24-84.62
Q04 2019-0.33-0.2815.15
Q03 2019-0.33-0.37-12.12
Q02 2019-0.35-0.42-20.00
Earnings Per EndEstimateRevision %Trend
6/2021 QR-0.250.00-
9/2021 QR-0.263.70Positive
12/2021 FY-1.004.76Positive
12/2022 FY-1.069.40Positive
Next Report Date9th Aug 2021
Estimated EPS Next Report-0.25
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume348.77K
Shares Outstanding155.47M
Trades Count2.90K
Dollar Volume3.38M
Avg. Volume915.42K
Avg. Weekly Volume399.31K
Avg. Monthly Volume510.11K
Avg. Quarterly Volume836.97K

Adaptimmune Therapeutics plc (NASDAQ: ADAP) stock closed at 3.57 per share at the end of the most recent trading day (a -1.11% change compared to the prior day closing price) with a volume of 348.79K shares and market capitalization of 555.03M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 462 people. Adaptimmune Therapeutics plc CEO is Adrian Rawcliffe.

The one-year performance of Adaptimmune Therapeutics plc stock is -60.33%, while year-to-date (YTD) performance is -33.77%. ADAP stock has a five-year performance of -56.03%. Its 52-week range is between 3.37 and 10.93, which gives ADAP stock a 52-week price range ratio of 2.65%

Adaptimmune Therapeutics plc currently has a PE ratio of -4.10, a price-to-book (PB) ratio of 1.96, a price-to-sale (PS) ratio of 174.43, a price to cashflow ratio of 30.40, a PEG ratio of 2.32, a ROA of -39.07%, a ROC of -51.96% and a ROE of -55.10%. The company’s profit margin is -%, its EBITDA margin is -3 696.30%, and its revenue ttm is $3.13 Million , which makes it $0.02 revenue per share.

Of the last four earnings reports from Adaptimmune Therapeutics plc, there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.25 for the next earnings report. Adaptimmune Therapeutics plc’s next earnings report date is 09th Aug 2021.

The consensus rating of Wall Street analysts for Adaptimmune Therapeutics plc is Moderate Buy (2), with a target price of $9, which is +152.10% compared to the current price. The earnings rating for Adaptimmune Therapeutics plc stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Adaptimmune Therapeutics plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Adaptimmune Therapeutics plc has a Sell technical analysis rating based on Technical Indicators (ADX : 17.01, ATR14 : 0.20, CCI20 : -96.76, Chaikin Money Flow : 0.18, MACD : -0.19, Money Flow Index : 48.27, ROC : -4.29, RSI : 36.40, STOCH (14,3) : 32.79, STOCH RSI : 0.65, UO : 35.67, Williams %R : -67.21), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Adaptimmune Therapeutics plc in the last 12-months were: Adrian Rawcliffe (Sold 23 135 shares of value $137 125 ), Elliot Norry (Sold 3 797 shares of value $21 644 ), Gavin Hilary James Wood (Buy at a value of $16 550), Helen Tayton-Martin (Option Excercise at a value of $280 245), John Lunger (Sold 11 304 shares of value $81 504 ), Lawrence M. Alleva (Buy at a value of $9 954), William C. Bertrand (Buy at a value of $143 824), William C. Bertrand (Sold 5 733 shares of value $32 386 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (50.00 %)
3 (60.00 %)
3 (60.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (50.00 %)
2 (40.00 %)
2 (40.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.00
Moderate Buy
1.80
Moderate Buy
1.80

Adaptimmune Therapeutics plc

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, NON-SMALL CELL LUNG CANCER, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.

CEO: Adrian Rawcliffe

Telephone: +44 1235430000

Address: 60 Jubilee Avenue, Abingdon OX14 4RY, Oxfordshire, GB

Number of employees: 462

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

78%22%

Bearish Bullish

59%41%

Bearish Bullish

62%38%

News

Stocktwits